NEW YORK (TheStreet) -- Tuesday featured two huge movers, with shares of Bluebird Bio (BLUE) up 57% and Conn's (CONN) down a whopping 40%. Let's starts with the good, said TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio.
On CNBC's "Cramer's Mad Dash" segment, Cramer explained that shares of Bluebird are higher due to the company's presentation at the American Society of Hematology conference in San Francisco.
Must Read: 7 Stocks Warren Buffett Is Selling in 2014
The company manufactures a drug that boosts hemoglobin without the use of a blood transfusion. This could be a "miracle drug for sickle cell anemia," Cramer said.
There is a lot of exciting news and data from the hematology conference, "but Bluebird is probably the biggest winner of all," Cramer said.
Now for the bad news. Shares of Conn's are lower after the company disappointed investors with its third-quarter earnings results. The company grew revenues 19% year-over-year, but reported an enormous earnings-per-share miss, losing 8 cents per share in the quarter.
So even though shares of Conn's -- which was once a great growth story -- are trading at a large discount, investors should avoid the stock.